<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article article-type="other" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">
  <front>
    <journal-meta>
      <journal-id journal-id-type="pmc">JRMS</journal-id>
      <journal-id journal-id-type="pubmed">J Res Med Sci</journal-id>
      <journal-id journal-id-type="publisher-id">Journal of Research in Medical Sciences</journal-id>
      <journal-title>Journal of Research in Medical Sciences</journal-title>
      <issn pub-type="ppub">1735-1995</issn>
	<issn pub-type="epub">1735-7136</issn>
      <publisher>
        <publisher-name>Medknow Publications Pvt Ltd</publisher-name>
	<publisher-loc>India</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id">JRMS-18-370</article-id>
      <article-id pub-id-type="pmid">24174938</article-id>
      <article-categories>
	<subj-group subj-group-type="headings">
		<subject>Original Article</subject>
	</subj-group>
      </article-categories>
      <title-group>
        <article-title>A model for prediction of cisplatin induced nephrotoxicity by kidney weight in experimental rats
</article-title>
      </title-group>
	<contrib-group>
<contrib contrib-type="author">
<name><surname>Nematbakhsh</surname>
<given-names>Mehdi</given-names></name>
<xref ref-type="aff" rid="aff1"/></contrib>
<contrib contrib-type="author">
<name><surname>Ashrafi</surname>
<given-names>Farzaneh</given-names></name>
<xref ref-type="aff" rid="aff2"/><xref ref-type="corresp" rid="cor1"/></contrib>
<contrib contrib-type="author">
<name><surname>Nasri</surname>
<given-names>Hamid</given-names></name>
<xref ref-type="aff" rid="aff3"/></contrib>
<contrib contrib-type="author">
<name><surname>Talebi</surname>
<given-names>Ardeshir</given-names></name>
<xref ref-type="aff" rid="aff4"/></contrib>
<contrib contrib-type="author">
<name><surname>Pezeshki</surname>
<given-names>Zahra</given-names></name>
<xref ref-type="aff" rid="aff5"/></contrib>
<contrib contrib-type="author">
<name><surname>Eshraghi</surname>
<given-names>Fatemeh</given-names></name>
<xref ref-type="aff" rid="aff6"/></contrib>
<contrib contrib-type="author">
<name><surname>Haghighi</surname>
<given-names>Maryam</given-names></name>
<xref ref-type="aff" rid="aff7"/></contrib>
</contrib-group>
<aff id="aff1">Water and Electrolytes Research Center; Department of Physiology; Kidney Diseases Research Center, Isfahan, Iran</aff><aff id="aff2">Water and Electrolytes Research Center; Department of Hematology Oncology Division of Departments of Internal Medicine, Isfahan, Iran</aff><aff id="aff3">Water and Electrolytes Research Center; Kidney Diseases Research Center; Department of Hematology Oncology Division of Departments of Internal Medicine, Isfahan, Iran</aff><aff id="aff4">Water and Electrolytes Research Center; Department of Clinical Pathology, Isfahan University of Medical Sciences, Isfahan, Iran</aff><aff id="aff5">Water and Electrolytes Research Center, Isfahan, Iran</aff><aff id="aff6">Water and Electrolytes Research Center, Isfahan, Iran</aff><aff id="aff7">Water and Electrolytes Research Center, Isfahan, Iran</aff>

      <author-notes>
	<corresp id="cor1"><bold>Address for correspondence:</bold>Farzaneh Ashrafi, Water and Electrolytes Research Center, and Hematology Oncology Division of Department of Internal Medicine, Isfahan University of Medical Sciences, Isfahan, Iran <email xlink:href="f_ashrafi@med.mui.ac.ir">f_ashrafi@med.mui.ac.ir</email></corresp>

      </author-notes>
      <pub-date pub-type="ppub">
        <season>May</season>
        <year>2013</year>
      </pub-date>
      <volume>18</volume>
      <issue>5</issue>
      <fpage>370</fpage>
      <lpage>373</lpage>   
      
<history>
<date date-type="received"><day>20</day><month>8</month><year>2012</year></date>

<date date-type="rev-recd"><day>18</day><month>1</month><year>2013</year></date>
</history>

      <permissions>
        <copyright-statement>Copyright: &#x000a9; Journal of Research in Medical Sciences</copyright-statement>
        <copyright-year>2013</copyright-year>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0"><p>This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p>
</license>
      </permissions>
      <abstract><sec id="st1"><title>Background:</title><p> Cisplatin (cis-diamminedichloroplatinum II; CP) is used widely as an antitumor drug in clinics, but is accompanied with renal toxicity. Cisplatin induced nephrotoxicity consists of change in kidney weight, histological changes in kidney and increase in serum creatinine (Cr) and blood urea nitrogen (BUN). This study was designed to find out a model for prediction of cisplatin induced nephrotoxicity. <sec id="st1"><title>Materials and</title><p> <sec id="st1"><title>Methods:</title><p> Pathological damage score, kidney weight, BUN, and Cr of 227 rats that were involved in different projects were determined. A total of 187 rats were treated with 7 mg/kg cisplatin and sacrificed 1 week later. <sec id="st1"><title>Results:</title><p> There was a good significant correlation between normalized kidney weight and logarithmic scale of BUN and Cr. Relationship between BUN, Cr or normalized kidney weight and pathology damage score was significant. <sec id="st1"><title>Conclusion:</title><p> Normalized kidney weight and pathology damage score is a good predictor of renal function in cisplatin induced nephrotoxicity in experimental rats.</p>
</sec>
<sec id="st2"><title>Materials and</title><p> <sec id="st2"><title>Methods:</title><p> Pathological damage score, kidney weight, BUN, and Cr of 227 rats that were involved in different projects were determined. A total of 187 rats were treated with 7 mg/kg cisplatin and sacrificed 1 week later. <sec id="st2"><title>Results:</title><p> There was a good significant correlation between normalized kidney weight and logarithmic scale of BUN and Cr. Relationship between BUN, Cr or normalized kidney weight and pathology damage score was significant. <sec id="st2"><title>Conclusion:</title><p> Normalized kidney weight and pathology damage score is a good predictor of renal function in cisplatin induced nephrotoxicity in experimental rats.</p>
</sec>
<sec id="st3"><title>Methods:</title><p> Pathological damage score, kidney weight, BUN, and Cr of 227 rats that were involved in different projects were determined. A total of 187 rats were treated with 7 mg/kg cisplatin and sacrificed 1 week later. <sec id="st3"><title>Results:</title><p> There was a good significant correlation between normalized kidney weight and logarithmic scale of BUN and Cr. Relationship between BUN, Cr or normalized kidney weight and pathology damage score was significant. <sec id="st3"><title>Conclusion:</title><p> Normalized kidney weight and pathology damage score is a good predictor of renal function in cisplatin induced nephrotoxicity in experimental rats.</p>
</sec>
<sec id="st4"><title>Results:</title><p> There was a good significant correlation between normalized kidney weight and logarithmic scale of BUN and Cr. Relationship between BUN, Cr or normalized kidney weight and pathology damage score was significant. <sec id="st4"><title>Conclusion:</title><p> Normalized kidney weight and pathology damage score is a good predictor of renal function in cisplatin induced nephrotoxicity in experimental rats.</p>
</sec>
<sec id="st5"><title>Conclusion:</title><p> Normalized kidney weight and pathology damage score is a good predictor of renal function in cisplatin induced nephrotoxicity in experimental rats.</p>
</sec>
</abstract>
      <kwd-group><kwd>Cisplatin</kwd>
<kwd>kidney weight</kwd>
<kwd>nephrotoxicity</kwd>
<kwd>pathology</kwd>
<kwd>rat</kwd>
</kwd-group>	
      
    </article-meta>
  </front>
  <body>
	<sec><title/>
</sec><sec><title>Introduction</title><p>Cisplatin (cis-diamminedichloroplatinum II, CP) is a potent antitumor drug for a wide variety of tumors such as head, neck, lung, testis, ovary, and breast. <sup><xref ref-type="bibr" rid="ref1">1</xref></sup> CP leads to accumulation of platinum within the kidney and disturb renal tubular tissue and function. <sup><xref ref-type="bibr" rid="ref2">2</xref></sup> The renal dysfunction; renal toxicity induced by CP is involved tubular epithelial cell toxicity, apoptosis, vasoconstriction in the renal microvasculature, proinflammatory effects and activating mitogen-activated protein kinases. <sup><xref ref-type="bibr" rid="ref2">2</xref></sup>,<sup><xref ref-type="bibr" rid="ref3">3</xref></sup> The CP-induced nephrotoxicity is manifested by increased serum level of blood urea nitrogen (BUN) and creatinine (Cr) as well as various histological aspects of kidney tissue.</p>

<p>The weight of kidneys tissue is another aspect that may change in CP-induced nephrotoxicity. It is reported that in animals treated with CP, the normalized kidneys weight increased, and it was correlated with intensity of tissue damage. <sup><xref ref-type="bibr" rid="ref4">4</xref></sup>,<sup><xref ref-type="bibr" rid="ref5">5</xref></sup> Clinically, kidney tissue biopsy is an invasive procedure to evaluate the kidney damage that should be avoided in non-critical conditions hence the most available non-invasive parameters to evaluate the toxicity induced by drug such as CP is the serum level of BUN and Cr. The relationships between these non-invasive parameters with intensity of kidney tissue damage provide more knowledge to understand, to interpret, and to avoid the CP-induced nephrotoxicity. Therefore, in this study, we tried to demonstrate the relationship between the histopathology damage scores and the weight of kidneys, as well as the relationship between the BUN or Cr and kidneys damage and weight in a large number of Wistar rats.</p>


</sec><sec sec-type='materials|methods'><title>Materials and Methods</title><p>The investigation was performed on Wistar rats. The rats were housed at a temperature of 23-25&#176;C. The rats had free access to water and rat chow, and they were acclimatized to this diet for at least 1 week prior to the experiment. The experimental procedures were approved in advance by the Isfahan University Medical Sciences Ethics Committee.</p>

<p>In past 3 years (from 2009 to 2012) that our teams in Water and Electrolytes Research Center have been worked in the different projects on CP and its nephrotoxicity side-effect, 227 (170-220 g) rats were studied; 40 rats did not treated with CP; normal, and 187 rats received CP (7 mg/kg, ip) as a single dose, and they sacrificed 1 week later. Based on the projects, the treated rats received different supplementations to protect against CP induced nephrotoxicity. At the end of the experiment, the kidney was removed and weighted rapidly. The levels of serum Cr and BUN were determined using the quantitative diagnostic kits (Pars Azmoon, Iran). The removed kidney was fixed in 10&#x0025; neutral formalin solution and was embedded in paraffin for the histopathological staining. The hematoxylin and eosin, stain was applied to examine the tubular atrophy, cast, debris and necrotic material in the tubular lumen and lymphocytes in interstitial tissue were considered as damage in tubules. Based on the intensity of tubular lesions as mentioned above, we scored from 1 to 4 while the score of zero was assigned to normal tubules without damage.</p>

<p> Statistical analysis</p>

<p> Statistical analysis was carried out with SPSS version 16. Data are expressed as mean &#177; SEM The serum levels of BUN, Cr and normalized kidney weight between each kidney tissue damage score were compared using one-way ANOVA. To obtain a relationship between BUN or Cr with normalized kidney weight, linear regression was applied. Values of P &lt; 0.05 were considered statistically significant.</p>


</sec><sec><title>Results</title><p>The relationship between the serum levels of BUN, Cr, or normalized kidneys weight and the pathology damage score are shown in <xref ref-type="fig" rid="F1">Figure 1</xref>. As pathology damage score increases, the serum levels of BUN and Cr, and the kidney weight increase. The normalized kidney weight also was correlated with the logarithmic scale of the serum level s of BUN and Cr significantly ( P &lt; 0.05) <xref ref-type="fig" rid="F2">Figure 2</xref>.<fig id="F1"><label>Figure 1</label><caption><p>The relationship between the serum levels of blood urea nitrogen, creatinine, or normalized kidneys weight and pathology damage score. The signs indicate a significant difference from (FNx01) score 0, (#) score 1, (&#8224;) score 2, or ($) score3, P &lt; 0.05</p>
</caption><alt-text>Figure 1</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="JResMedSci_2013_18_5_370_119207_u1.tif"/></fig><fig id="F2"><label>Figure 2</label><caption><p>The relationship between the serum levels of blood urea nitrogen or creatinine (in logarithmic scale) with the normalized kidneys weight</p>
</caption><alt-text>Figure 2</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="JResMedSci_2013_18_5_370_119207_u2.tif"/></fig></p>

<p>For Cr: Log (10 Cr) =0.239 (SE = 0.093, P = 0.011) &#x002B; 0.924 KW (SE = 0.098, P = 0.00)</p>

<p>For BUN: Log BUN = 0.845(SE = 0.082, P = 0.00) &#x002B; 0.995KW (SE = 0.086, P = 0.00)</p>


</sec><sec><title>Discussion</title><p>CP nephrotoxicity primarily causes tubulo interstitial lesions. <sup><xref ref-type="bibr" rid="ref6">6</xref></sup> In animal models CP damages the proximal tubules, specifically the S3 segment in the outer medulla. <sup><xref ref-type="bibr" rid="ref6">6</xref></sup>,<sup><xref ref-type="bibr" rid="ref7">7</xref></sup> Mitochondrial swelling and nuclear pallor occur in the distal nephron. The glomerulus has no obvious morphologic changes. <sup><xref ref-type="bibr" rid="ref8">8</xref></sup> In this report, the pathological damage in CP treated rats was in tubules, and a grading model based on the intensity of tubular lesions (tubular atrophy, cast, debris, and necrotic material in the tubular lumen and lymphocyte in interstitial tissue) was developed for report of tubular damage, and its intensity in CP treated experimental rats.</p>

<p>Our analysis showed that this grading model had a good and acceptable correlation with the serum BUN and Cr (in logarithmic scale) level in CP treated rats. This finding seems to be sufficient to suggest a comment for the clinician to collect the similar data from patients who are subjected for kidney biopsy to verify or reject the correlation between biochemical and the histopathological data in human subject.</p>

<p>In previous reports of CP nephrotoxicity, pathological damage after CP treatment had been reported; <sup><xref ref-type="bibr" rid="ref8">8</xref></sup>,<sup><xref ref-type="bibr" rid="ref9">9</xref></sup>,<sup><xref ref-type="bibr" rid="ref10">10</xref></sup> however, there were no scoring system for the report of intensity of CP induced pathological damage.</p>

<p>The toxic kidneys gain weight as the damage increase. <sup><xref ref-type="bibr" rid="ref5">5</xref></sup>,<sup><xref ref-type="bibr" rid="ref7">7</xref></sup>,<sup><xref ref-type="bibr" rid="ref11">11</xref></sup>,<sup><xref ref-type="bibr" rid="ref12">12</xref></sup> On the other hand in CP treated rats decrease in body weight had been reported, <sup><xref ref-type="bibr" rid="ref5">5</xref></sup>,<sup><xref ref-type="bibr" rid="ref11">11</xref></sup>,<sup><xref ref-type="bibr" rid="ref13">13</xref></sup> and polyuria is a well-known phenomenon. <sup><xref ref-type="bibr" rid="ref12">12</xref></sup> It seems that decrease in urine concentrating ability secondary to decrease in the papillary hyper tonicity is the main cause of decrease in body weight. <sup><xref ref-type="bibr" rid="ref14">14</xref></sup>,<sup><xref ref-type="bibr" rid="ref15">15</xref></sup> Therefore, the kidney gain weight is not induced by body weight change or urination process disturbance.</p>

<p>In accordance with the other reports with a small number of an experimental rats <sup><xref ref-type="bibr" rid="ref5">5</xref></sup>,<sup><xref ref-type="bibr" rid="ref11">11</xref></sup>,<sup><xref ref-type="bibr" rid="ref12">12</xref></sup>,<sup><xref ref-type="bibr" rid="ref13">13</xref></sup> in the present study, the normalized kidney weight in a large number of CP treated rats was increased as kidney damage increase <xref ref-type="fig" rid="F1">Figure 1</xref>. In conclusion, it seems that change in the normalized kidney weight could be a good predictor of the pathological damage in experimental models and a reliable predictor of increase in serum Cr and BUN as well.</p>
</sec>
  </body>
  <back>
	
	
	    <ref-list><ref id="ref1">
<label>1</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author"><name> 
  <surname>Arany</surname>
  <given-names>I</given-names>
</name>
<name> 
  <surname>Safirstein</surname>
  <given-names>RL</given-names>
</name>
</person-group><article-title>Cisplatin nephrotoxicity</article-title><source>Semin Nephrol</source>
<year>2003</year>
<volume>23</volume>
<fpage>460</fpage>
<lpage>4</lpage>
</nlm-citation>
</ref>
<ref id="ref2">
<label>2</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author"><name> 
  <surname>Miller</surname>
  <given-names>RP</given-names>
</name>
<name> 
  <surname>Tadagavadi</surname>
  <given-names>RK</given-names>
</name>
<name> 
  <surname>Ramesh</surname>
  <given-names>G</given-names>
</name>
<name> 
  <surname>Reeves</surname>
  <given-names>WB</given-names>
</name>
</person-group><article-title>Mechanisms of Cisplatin nephrotoxicity</article-title><source>Toxins (Basel)</source>
<year>2010</year>
<volume>2</volume>
<fpage>2490</fpage>
<lpage>518</lpage>
</nlm-citation>
</ref>
<ref id="ref3">
<label>3</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author"><name> 
  <surname>Saad</surname>
  <given-names>SY</given-names>
</name>
<name> 
  <surname>Al-Rikabi</surname>
  <given-names>AC</given-names>
</name>
</person-group><article-title>Protection effects of Taurine supplementation against cisplatin-induced nephrotoxicity in rats</article-title><source>Chemotherapy</source>
<year>2002</year>
<volume>48</volume>
<fpage>42</fpage>
<lpage>8</lpage>
</nlm-citation>
</ref>
<ref id="ref4">
<label>4</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author"><name> 
  <surname>Saad</surname>
  <given-names>SY</given-names>
</name>
<name> 
  <surname>Najjar</surname>
  <given-names>TA</given-names>
</name>
<name> 
  <surname>Daba</surname>
  <given-names>MH</given-names>
</name>
<name> 
  <surname>Al-Rikabi</surname>
  <given-names>AC</given-names>
</name>
</person-group><article-title>Inhibition of nitric oxide synthase aggravates cisplatin-induced nephrotoxicity: Effect of 2-amino-4-methylpyridine</article-title><source>Chemotherapy</source>
<year>2002</year>
<volume>48</volume>
<fpage>309</fpage>
<lpage>15</lpage>
</nlm-citation>
</ref>
<ref id="ref5">
<label>5</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author"><name> 
  <surname>Haghighi</surname>
  <given-names>M</given-names>
</name>
<name> 
  <surname>Nematbakhsh</surname>
  <given-names>M</given-names>
</name>
<name> 
  <surname>Talebi</surname>
  <given-names>A</given-names>
</name>
<name> 
  <surname>Nasri</surname>
  <given-names>H</given-names>
</name>
<name> 
  <surname>Ashrafi</surname>
  <given-names>F</given-names>
</name>
<name> 
  <surname>Roshanaei</surname>
  <given-names>K</given-names>
</name>
 <etal/>
</person-group><article-title>The role of angiotensin II receptor 1 (AT1) blockade in cisplatin-induced nephrotoxicity in rats: Gender-related differences</article-title><source>Ren Fail</source>
<year>2012</year>
<volume>34</volume>
<fpage>1046</fpage>
<lpage>51</lpage>
</nlm-citation>
</ref>
<ref id="ref6">
<label>6</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author"><name> 
  <surname>Yao</surname>
  <given-names>X</given-names>
</name>
<name> 
  <surname>Panichpisal</surname>
  <given-names>K</given-names>
</name>
<name> 
  <surname>Kurtzman</surname>
  <given-names>N</given-names>
</name>
<name> 
  <surname>Nugent</surname>
  <given-names>K</given-names>
</name>
</person-group><article-title>Cisplatin nephrotoxicity: A review</article-title><source>Am J Med Sci</source>
<year>2007</year>
<volume>334</volume>
<fpage>115</fpage>
<lpage>24</lpage>
</nlm-citation>
</ref>
<ref id="ref7">
<label>7</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author"><name> 
  <surname>Pratibha Ravindra</surname>
  <given-names>DA</given-names>
</name>
<name> 
  <surname>Kulkarni</surname>
  <given-names>SS</given-names>
</name>
<name> 
  <surname>Padmanabh</surname>
  <given-names>V</given-names>
</name>
</person-group><article-title>Rataboli Chitra Y.Dhume KU</article-title><source>Cisplatin induced histological changes in renal tissue of rat</source>
<year></year>
<volume></volume>
<fpage></fpage>
<comment> Rataboli Chitra Y Dhume KU Cisplatin induced histological changes in renal tissue of rat J Cell Anim Biol 2010;4:108-11</comment>
</nlm-citation>
</ref>
<ref id="ref8">
<label>8</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author"><name> 
  <surname>Vickers</surname>
  <given-names>AE</given-names>
</name>
<name> 
  <surname>Rose</surname>
  <given-names>K</given-names>
</name>
<name> 
  <surname>Fisher</surname>
  <given-names>R</given-names>
</name>
<name> 
  <surname>Saulnier</surname>
  <given-names>M</given-names>
</name>
<name> 
  <surname>Sahota</surname>
  <given-names>P</given-names>
</name>
<name> 
  <surname>Bentley</surname>
  <given-names>P</given-names>
</name>
</person-group><article-title>Kidney slices of human and rat to characterize cisplatin-induced injury on cellular pathways and morphology</article-title><source>Toxicol Pathol</source>
<year>2004</year>
<volume>32</volume>
<fpage>577</fpage>
<lpage>90</lpage>
</nlm-citation>
</ref>
<ref id="ref9">
<label>9</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author"><name> 
  <surname>Choie</surname>
  <given-names>DD</given-names>
</name>
<name> 
  <surname>Longnecker</surname>
  <given-names>DS</given-names>
</name>
<name> 
  <surname>del Campo</surname>
  <given-names>AA</given-names>
</name>
</person-group><article-title>Acute and chronic cisplatin nephropathy in rats</article-title><source>Lab Invest</source>
<year>1981</year>
<volume>44</volume>
<fpage>397</fpage>
<lpage>402</lpage>
</nlm-citation>
</ref>
<ref id="ref10">
<label>10</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author"><name> 
  <surname>Nosaka</surname>
  <given-names>K</given-names>
</name>
<name> 
  <surname>Nakada</surname>
  <given-names>J</given-names>
</name>
<name> 
  <surname>Endou</surname>
  <given-names>H</given-names>
</name>
</person-group><article-title>Cisplatin-induced alterations in renal structure, ammoniagenesis and gluconeogenesis of rats</article-title><source>Kidney Int</source>
<year>1992</year>
<volume>41</volume>
<fpage>73</fpage>
<lpage>9</lpage>
</nlm-citation>
</ref>
<ref id="ref11">
<label>11</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author"><name> 
  <surname>Nematbakhsh</surname>
  <given-names>M</given-names>
</name>
<name> 
  <surname>Ashrafi</surname>
  <given-names>F</given-names>
</name>
<name> 
  <surname>Safari</surname>
  <given-names>T</given-names>
</name>
<name> 
  <surname>Talebi</surname>
  <given-names>A</given-names>
</name>
<name> 
  <surname>Nasri</surname>
  <given-names>H</given-names>
</name>
<name> 
  <surname>Mortazavi</surname>
  <given-names>M</given-names>
</name>
 <etal/>
</person-group><article-title>Administration of vitamin E and losartan as prophylaxes in cisplatin-induced nephrotoxicity model in rats</article-title><source>J Nephrol</source>
<year>2012</year>
<volume>25</volume>
<fpage>410</fpage>
<lpage>7</lpage>
</nlm-citation>
</ref>
<ref id="ref12">
<label>12</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author"><name> 
  <surname>Shimeda</surname>
  <given-names>Y</given-names>
</name>
<name> 
  <surname>Hirotani</surname>
  <given-names>Y</given-names>
</name>
<name> 
  <surname>Akimoto</surname>
  <given-names>Y</given-names>
</name>
<name> 
  <surname>Shindou</surname>
  <given-names>K</given-names>
</name>
<name> 
  <surname>Ijiri</surname>
  <given-names>Y</given-names>
</name>
<name> 
  <surname>Nishihori</surname>
  <given-names>T</given-names>
</name>
 <etal/>
</person-group><article-title>Protective effects of capsaicin against cisplatin-induced nephrotoxicity in rats</article-title><source>Biol Pharm Bull</source>
<year>2005</year>
<volume>28</volume>
<fpage>1635</fpage>
<lpage>8</lpage>
</nlm-citation>
</ref>
<ref id="ref13">
<label>13</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author"><name> 
  <surname>Salama</surname>
  <given-names>RH</given-names>
</name>
</person-group><article-title>Matricaria chamomilla attenuates cisplatin nephrotoxicity</article-title><source>Saudi J Kidney Dis Transpl</source>
<year>2012</year>
<volume>23</volume>
<fpage>765</fpage>
<lpage>72</lpage>
</nlm-citation>
</ref>
<ref id="ref14">
<label>14</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author"><name> 
  <surname>Safirstein</surname>
  <given-names>R</given-names>
</name>
<name> 
  <surname>Miller</surname>
  <given-names>P</given-names>
</name>
<name> 
  <surname>Dikman</surname>
  <given-names>S</given-names>
</name>
<name> 
  <surname>Lyman</surname>
  <given-names>N</given-names>
</name>
<name> 
  <surname>Shapiro</surname>
  <given-names>C</given-names>
</name>
</person-group><article-title>Cisplatin nephrotoxicity in rats: Defect in papillary hypertonicity</article-title><source>Am J Physiol</source>
<year>1981</year>
<volume>241</volume>
<fpage>F175</fpage>
<lpage>85</lpage>
</nlm-citation>
</ref>
<ref id="ref15">
<label>15</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author"><name> 
  <surname>Wilson</surname>
  <given-names>DR</given-names>
</name>
<name> 
  <surname>Honrath</surname>
  <given-names>U</given-names>
</name>
</person-group><article-title>Collecting duct function in cis-platinum nephrotoxicity</article-title><source>Can J Physiol Pharmacol</source>
<year>1987</year>
<volume>65</volume>
<fpage>1200</fpage>
<lpage>4</lpage>
</nlm-citation>
</ref>
<ref id="ref16">
<label>16</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author"></person-group><article-title></article-title><source></source>
<year></year>
<volume></volume>
<fpage></fpage>
</nlm-citation>
</ref>
</ref-list>

  </back>
	
</article> 




